You are here » Home » Companies » Company Overview » Anuh Pharma Ltd

Anuh Pharma Ltd.

BSE: 506260 Sector: Health care
NSE: N.A. ISIN Code: INE489G01022
BSE LIVE 12:01 | 20 Feb 214.00 4.20
(2.00%)
OPEN

211.50

HIGH

216.85

LOW

208.90

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 211.50
PREVIOUS CLOSE 209.80
VOLUME 1436
52-Week high 290.00
52-Week low 159.00
P/E 29.56
Mkt Cap.(Rs cr) 536.28
Buy Price 213.05
Buy Qty 196.00
Sell Price 214.00
Sell Qty 50.00
OPEN 211.50
CLOSE 209.80
VOLUME 1436
52-Week high 290.00
52-Week low 159.00
P/E 29.56
Mkt Cap.(Rs cr) 536.28
Buy Price 213.05
Buy Qty 196.00
Sell Price 214.00
Sell Qty 50.00

Anuh Pharma Ltd. (ANUHPHARMA) - Company History

Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group. Anuh Pharma Ltd was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs. The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries. During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg. During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production. In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption. In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption. In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.